Scientific Program – GYNECOLOGYFriday, November 28 & Saturday, November 29, 2025 |
 |
Friday, November 28
| 08:30-09:00 | GOOD MORNING ROME PLENARY LECTURE | Live streamed from HALL A |
| Capsule | A decade ago, a pioneering procedure was successfully launched | |
| Chairpersons | Zion Ben Rafael, Israel Rene Frydman, France |
|
| 08:30-08:55 | Pioneering uterus transplantation: Reflections on breakthroughs and deliveries Mats Brännström, Sweden |
|
| 08:55-09:00 | Discussion | |
| 09:00-10:00 | THE GUT, VAGINAL AND BLADDER MICROBIOME IN WOMEN’S LIFESPAN | HALL C |
| Capsule | Microbiome, so much information, yet so little clinical conclusion | |
| Chairpersons | Andrea Genazzani, Italy Mark Brincat, Malta |
|
| 09:00-09:15 |
The gut microbiome. The great director of women’s health |
|
| 09:15-09:20 |
Discussion |
|
| 09:20-09:35 |
The vaginal and bladder microbiome: The secret dialogue, in the lifespan |
|
| 09:35-09:40 |
Discussion |
|
| 09:40-09:55 |
The vaginal microbiome as a marker of female infertility |
|
| 09:55-10:00 |
Discussion |
|
| 10:00-10:30 | Coffee break, visit the exhibition, and e-poster viewing |
| 10:30-12:00 | NOVEL GLOBAL GUIDANCE ON POI: TOWARDS PERSONALIZED MEDICINE | HALL C |
| Capsule | ||
| Chairpersons | Nick Panay, UK Micheline Misrahi, France |
|
| 10:30-10:55 |
Genetics of POI: A leap for diagnosis and personalized medicine in novel 2024 guidelines |
|
| 10:55-11:15 |
Autoimmunity in POI |
|
| 11:15-11:40 |
GSM and sexual health in POI women |
|
| 11:40-12:00 |
Update of POI guidelines (from ESHRE and our latest searches of literature for IMS POI recommendations) |
|
| 12:00-12:05 | Short break |
| 12:05-13:05 | INDUSTRY SUPPORTED SESSION | HALL A and B |
| 13:05-14:00 | Lunch break, visit the exhibition, e-poster viewing, and moderated e-poster sessions |
| 14:00-15:00 | INDUSTRY SUPPORTED SESSION | HALL A and B |
| 15:00-15:05 | Short break |
| 15:05-16:35 | TREATING MENOPAUSE | HALL C |
| Capsule | All aging women deal with menopause, and associated symptoms. The extent of discomfort associated with menopause varies greatly. In addition, menopause is associated with long-term health risks. When should women be treated, what are preferred regimens, and for how long | |
| Chairpersons | Andrea Genazzani, Italy Alessandra Graziottin, Italy |
|
| 15:05-15:35
15:05 |
Debate: Patients with early menopause should be treated continuously to prevent chronic diseases For: Nick Panay, UK |
|
| 15:35-16:05
15:35 |
Debate: Menopause symptoms and diseases can be managed without Menopausal HT? For: Santiago Palacios, Spain |
|
| 16:05-16:35
16:05 |
Debate: Lichen Sclerosus or Vulvodynia Lichen Sclerosis: Zdenko Vizintin, Slovenia |
|
| 16:35-17:00 | Coffee break, visit the exhibition, and e-poster viewing |
| 17:00-18:30 | MENOPAUSE: BEYOND THE MINIMISATION OF HOT FLUSHES | HALL C |
| Capsule | HRT can positively affect most almost every system in the body | |
| Chairpersons |
Rossella Nappi, Italy |
|
| 17:00-17:15 |
Have we gone a full circle and should offer HT for all? |
|
| 17:15-17:20 |
Discussion |
|
| 17:20-17:40 |
Predicting, preventing and optimising cardiometabolic menopause outcomes in “at risk” women |
|
| 17:40-17:45 |
Discussion |
|
| 17:45-18:00 |
The bladder after the menopause: A call for action |
|
| 18:00-18:05 |
Discussion |
|
| 18:05-18:25 |
Osteoarthritis: Why estrogens have a specific role |
|
| 18:25-18:30 |
Discussion |
|
Saturday, November 29
| 08:30-10:00 | GOOD MORNING ROME PLENARY LECTURE | Live streamed from HALL A |
| Capsule | Endometriosis is a chronic disease that affects all phases of reproductive life | |
| Chairpersons |
Bart Fauser, Netherlands |
|
| 08:30-08:55 |
Endometriosis before and during pregnancy |
|
| 08:55-09:00 | Discussion | |
| 09:00-10:30 | ADENOMYOSIS AND ENDOMETRIOSIS | HALL C |
| Capsule | Adenomyosis hard to diagnose, difficult to manage | |
| Chairpersons | Pierluigi Benedetti Panici, Italy Jessica Ybanez Morano,USA |
|
| 09:00-09:20 |
Adenomyosis: Are we ready for personalized treatment? |
|
| 09:20-09:25 |
Discussion |
|
| 09:25-09:45 | Adenomyosis: Developing organoids for personalized treatment Marie-Madeline Dolmans, Belgium |
|
| 09:45-09:50 |
Discussion |
|
| 09:50-10:15 | Management and treatment options: What are the future directions? Jessica Ybanez Morano, USA |
|
| 10:15-10:20 |
Discussion |
|
| 10:20-10:30 |
General discussion |
|
| 10:30-11:00 | Coffee break, visit the exhibition, and e-poster viewing |
| 11:00-12:30 | FERTILITY PRESERVATION | HALL C |
| Capsule | With improved long-term prognosis of cancer treatment in young women, the preservation of future fertility has become of greater significance. For which patients should fertility preservation be offered, and what are best ways to do so | |
| Chairpersons |
Jacques Donnez, Belgium |
|
| 11:00-11:15 | Fertility – sparing management in recurrent gynecological cancer Pierluigi Benedetti Panici, Italy |
|
| 11:15-11:20 | Discussion | |
| 11:20-11:35 | Fertility preservation in borderline and malignant tumors Michael Grynberg, France |
|
| 11:35-11:40 | Discussion | |
| 11:40-12:10
11:40 |
Debate: Is there room for ovarian tissue cryopreservation for breast cancer patients? What is the risk?
Yes: Michael Grynberg, France |
|
| 12:10-12:25 | What are the differences between fertility preservation for benign diseases and malignancy? Stratis Kolibianakis, Greece |
|
| 12:25-12:30 | Discussion | |
| 12:30-13:30 | Lunch break, visit the exhibition, and e-poster viewing |
| 13:30-15:00 | PCOS | HALL C |
| Capsule | The diagnostic criteria of the notoriously heterogeneous condition PCOS is a matter of continued debate. Women may visit the clinic at different ages, and with different complaints. Accordingly, the impact of different diagnostic criteria may vary accordingly. Recently, modified criteria have been suggested for adolescent women and ultrasound may be replaced by AMH | |
| Chairpersons |
Anja Pinborg, Denmark |
|
| 13:30-14:00
13:30 |
Debate: Is the diagnostic criteria for PCOS adequate for effective management? Yes: Stefano Palomba, Italy |
|
| 13:50-14:05 |
SEMaglutides (GLP1 antagonist) and PCO |
|
| 14:05-14:10 | Discussion | |
| 14:10-14:25 |
Challenges in diagnosing PCOS in adolescents |
|
| 14:25-14:30 |
Discussion |
|
| 15:00-16:30 | MANAGING SEXUAL ISSUES | HALL C |
| Capsule | Regarding sexual issues with menopause, we should replace the “don’t ask, don’t tell” strategy with “Ask, diagnose and offer treatment” | |
| Chairpersons |
Nick Panay, UK |
|
| 15:00-15:15 |
There is a need for androgen therapy after menopause |
|
| 15:15-15:20 |
Discussion |
|
| 15:20-15:40 | Neurokinin-3 receptor antagonists: A novel approach to treating menopausal vasomotor symptoms Santiago Palacios, Spain |
|
| 15:40-15:45 |
Discussion |
|
| 15:45-16:05 |
Sexual arousal: The winning strategy |
|
| 16:05-16:10 |
Discussion |
|
| 16:10-16:25 |
Managing sexuality issues in patients contraindicated to or unresponsive to estrogens and androgens |
|
| 16:25-16:30 |
Discussion |
|
